Axa lessened its stake in shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) by 28.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 311,020 shares of the medical research company’s stock after selling 121,627 shares during the period. Axa owned about 0.56% of Accelerate Diagnostics worth $8,149,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of AXDX. Cpwm LLC bought a new position in Accelerate Diagnostics during the fourth quarter worth about $202,000. UBS Asset Management Americas Inc. bought a new position in Accelerate Diagnostics during the fourth quarter worth about $233,000. Teacher Retirement System of Texas bought a new position in Accelerate Diagnostics during the fourth quarter worth about $292,000. Thompson Investment Management Inc. bought a new position in Accelerate Diagnostics during the third quarter worth about $393,000. Finally, The Manufacturers Life Insurance Company boosted its position in Accelerate Diagnostics by 13.0% during the second quarter. The Manufacturers Life Insurance Company now owns 21,125 shares of the medical research company’s stock worth $578,000 after purchasing an additional 2,425 shares during the period. Institutional investors and hedge funds own 44.86% of the company’s stock.
Accelerate Diagnostics Inc (NASDAQ:AXDX) opened at $25.40 on Wednesday. Accelerate Diagnostics Inc has a 1 year low of $16.75 and a 1 year high of $30.45. The company has a market cap of $1,420.00, a P/E ratio of -21.53 and a beta of 2.22.
In other news, Director Jack W. Schuler acquired 15,000 shares of the business’s stock in a transaction dated Thursday, March 1st. The stock was bought at an average cost of $25.15 per share, for a total transaction of $377,250.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jack W. Schuler acquired 10,000 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was purchased at an average price of $25.21 per share, with a total value of $252,100.00. The disclosure for this purchase can be found here. Insiders bought 45,100 shares of company stock valued at $1,130,850 over the last 90 days. 50.00% of the stock is owned by company insiders.
A number of brokerages have weighed in on AXDX. ValuEngine lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. BidaskClub upgraded shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research report on Thursday, February 22nd. BTIG Research reiterated a “hold” rating on shares of Accelerate Diagnostics in a research report on Sunday, February 18th. Finally, Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday, January 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $33.00.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics Inc (NASDAQ:AXDX).
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.